Organization
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
10 abstracts
Abstract
Primary localized malignant PEComa treated with surgery: A report of a large series of patients treated in a referral institution.Org: Unit of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,
Abstract
A phase II study of tinostamustine in patients (pts) with advanced solid tumours.Org: Mary Crowley Cancer Research, University of Michigan, European Institute of Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain,
Abstract
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.Org: Humanitas University, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, IRCCS Humanitas Research Hospital, Rozzano, Italy, Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, Hospital Clínic Barcelona,
Abstract
Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliera Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, University of Pisa, Pisa, Italy, University Campus Biomedico,
Abstract
Outcome of patients (PTS) with advanced epithelioid hemangioendothelioma (EHE) after failure on sirolimus (S).Org: Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Istituto Oncologico Veneto IOV-IRCCS, Department of Medical Oncology, Fondazione Policlinico Campus Bio-Medico, Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,
Abstract
Prolonged 14-day continuous infusion of high-dose ifosfamide (14IFO) for relapsed/refractory high-grade osteosarcoma (R/R HOS): A retrospective multicenter cohort study.Org: Pediatric Onco-Hematology Department, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza, Turin, Italy, Regina Margherita Children's Hospital, AOU Città della Salute e della Scienza di Torino, University of Torino, Centre for Biostatistics, Epidemiology and Public Health,
Abstract
Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.Org: University of Brescia, ASST Spedali Civili - Brescia, University Hospital of Parma, University of Pisa, Pisa, Italy, ATC Innovation Lab,
Abstract
Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).Org: IRCCS Foundation National Cancer Institute, Milan, Italy, Molinette Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fondazione Policlinico Campus Bio-Medico, Orthopaedic Institute Rizzoli,
Abstract
NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Head and Neck Cancer Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan,
Abstract
Italian report of expanded access for nab-sirolimus in patients with malignant perivascular epithelioid cell tumor (PEComa).Org: Instituto Tumori Milano, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, Istituto Nazionale Tumori Pascale, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy,